Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

The critical role of leukemia-initiating cells as a therapy-resistant population in myeloid leukemia is well established. However, the molecular signatures of such cells in acute lymphoblastic leukemia remain underexplored. Moreover, their role in therapy response and patient prognosis is yet to be systematically investigated across various types of acute leukemia. We used single-cell multiomics to analyze diagnostic specimens from 96 pediatric patients with acute lymphoblastic, myeloid, and lineage-ambiguous leukemias. Through the integration of single-cell multiomics with extensive bulk RNA sequencing and clinical data sets, we uncovered a prevalent, chemotherapy-resistant subpopulation that resembles hematopoietic stem and progenitor cells (HSPC-like) and is associated with poor clinical outcomes across all subtypes investigated. We identified a core transcriptional regulatory network (TRN) in HSPC-like blasts that is combinatorially controlled by HOXA/AP1/CEBPA. This TRN signature can predict chemotherapy response and long-term clinical outcomes. We identified shared potential therapeutic targets against HSPC-like blasts, including FLT3, BCL2, and the PI3K pathway. Our study provides a framework for linking intratumoral heterogeneity with therapy response, patient outcomes, and the discovery of new therapeutic targets for pediatric acute leukemias.

Authors

Institutions

Publication Details

Journal
Blood
Published
2025-03-16
DOI
https://doi.org/10.1182/blood.2024027270
Citations
10
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
17.70
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

Kai Tan, Mignon L. Loh, Brent Lee Wood, Jianzhong Hu et al.
10 citations
Blood
Acute Myeloid Leukemia Research
17.70
article

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome

Kai Tan, Mignon L. Loh, Brent Lee Wood, Jianzhong Hu, Stephen P. Hunger, Elizabeth A. Raetz, David T. Teachey, Gongping Shi, Fatemeh Alikarami‬, Petri Pölönen, Lahari Uppuluri, Austin Yang, Wenbao Yu, Andrew D. Hughes, Rawan Shraim, Haley Newman, Jacqueline Peng, Yangyang Ding, David B. Frank, Changya Chen, Charles Grenfell Mullighan, Satoshi Yoshimura, Jun J. Yang, Shovik Bandyopadhyay, Stanley Pounds, Caroline Diorio, Elizabeth Y Li, Tiffaney L. Vincent, Tori J. Fuller, Kathrin M. Bernt, Chia-Hui Chen, Joseph S. Tumulty, Jonathan Sussman, Theresa Ryan, Xiaohuan Qin, Jason Xu
article en
10 citations

Abstract

The critical role of leukemia-initiating cells as a therapy-resistant population in myeloid leukemia is well established. However, the molecular signatures of such cells in acute lymphoblastic leukemia remain underexplored. Moreover, their role in therapy response and patient prognosis is yet to be systematically investigated across various types of acute leukemia. We used single-cell multiomics to analyze diagnostic specimens from 96 pediatric patients with acute lymphoblastic, myeloid, and lineage-ambiguous leukemias. Through the integration of single-cell multiomics with extensive bulk RNA sequencing and clinical data sets, we uncovered a prevalent, chemotherapy-resistant subpopulation that resembles hematopoietic stem and progenitor cells (HSPC-like) and is associated with poor clinical outcomes across all subtypes investigated. We identified a core transcriptional regulatory network (TRN) in HSPC-like blasts that is combinatorially controlled by HOXA/AP1/CEBPA. This TRN signature can predict chemotherapy response and long-term clinical outcomes. We identified shared potential therapeutic targets against HSPC-like blasts, including FLT3, BCL2, and the PI3K pathway. Our study provides a framework for linking intratumoral heterogeneity with therapy response, patient outcomes, and the discovery of new therapeutic targets for pediatric acute leukemias.

BloodVol. 145(23)
Seattle Children's Hospital (US), St. Jude Children's Research Hospital (US), Amgen (United States) (US), Children's Hospital of Philadelphia (US), Children's Hospital of Los Angeles (US), Johns Hopkins University (US), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), University of Washington (US), Johns Hopkins Medicine (US), Yale University (US), NYU Langone Health (US), Seattle Children's Hospital (US), Center for Cancer and Blood Disorders (US), Institute of Hematology & Blood Diseases Hospital (CN), Sidney Kimmel Comprehensive Cancer Center (US), New York University (US), University of Pennsylvania (US), Philadelphia University (US)
Good health and well-being
Openalex Percentile: Top 1%
Acute Myeloid Leukemia Research
17.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.